Start Time: 16:30 January 1, 0000 5:35 PM ET Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2021 Earnings Conference Call March 01, 2022, 16:30 PM ET Company Participants Raul Rodriguez - President and CEO Wolfgang Dummer - EVP and CMO Dave Santos - EVP and Chief Commercial Officer Dean Schorno - EVP and CFO Dolly Vance - EVP, Corporate Affairs and General Counsel Conference Call Participants Do Kim - Piper Sandler Eun Yang - Jefferies Joe Pantginis - H.C. Wainwright Yigal Nochomovitz - Citigroup Kristen Klus ...

Q3 2021 Financial Presentation November 2, 2021 1 Forward-Looking Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, the commercial success of TAVALISSE in the U.S. and TAVLESSE in Europe, including the efficacy of its expanded sales force; expectations related to the potential and market opportunity for fostamatinib as therapeutic for, among other things, wAIHA and COVID-19; th ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2021 Results Conference Call November 2, 2021 4:30 PM ET Company Participants Dolly Vance - EVP, Corporate Affairs and General Counsel Raul Rodriguez - CEO Wolfgang Dummer - Chief Medical Officer Dave Santos - Chief Commercial Officer Dean Schorno - CFO Conference Call Participants Gary Nachman - BMO Capital Markets Joe Pantginis - H.C. Wainwright Kristen Kluska - Cantor Fitzgerald Operator Greetings, and welcome to Rigel Pharmaceuticals Financial Conference Call ...

August 3, 2021 Q2 2021 Financial Presentation Forward-Looking Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, the commercial success of TAVALISSE in the U.S. and TAVLESSE in Europe; Rigel's submission of an EUA application for fostamatinib for the treatment of hospitalized COVID-19 patients the commercial availability of fostamatinib; the three ongoing clinical studies on fos ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2021 Results Earnings Conference Call August 3, 2021 4:30 PM ET Company Participants Dolly Vance - Executive Vice President, Corporate Affairs and General Counsel Raul Rodriguez - President and Chief Executive Officer Wolfgang Dummer - Executive Vice President and Chief Medical Officer Dave Santos - Chief Commercial Officer Dean Schorno - Executive Vice President and Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Nicole Gabresk ...

June 2021 Corporate Presentation Forward-Looking Statement This presentation contains forward-looking statements relating to, among other things, the commercial success of TAVALISSE in the U.S. and TAVLESSE in Europe; Rigel's intention to apply for EUA for fostamatinib for the treatment of hospitalized COVID-19 patients; Rigel's ability to achieve development, regulatory and commercial milestone payments, as well as tiered royalties; expectations related to the market opportunity for fostamatinib as a COVID ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2021 Earnings Conference Call May 5, 2021 4:30 PM ET Company Participants Dolly Vance - Executive Vice President, Corporate Affairs and General Counsel Raul Rodriguez - President and Chief Executive Officer Dave Santos - Chief Commercial Officer Wolfgang Dummer - Executive Vice President and Chief Medical Officer Dean Schorno - Executive Vice President and Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Eun Yang - Jefferies Do K ...

May 2021 Q1 2021 Financial Presentation Forward-Looking Statement This presentation contains forward-looking statements relating to, among other things, the commercial success of TAVALISSE in the U.S. and TAVLESSE in Europe; Rigel's intention to apply for EUA for fostamatinib for the treatment of hospitalized COVID-19 patients; Rigel's ability to achieve development, regulatory and commercial milestone payments, as well as tiered royalties; expectations related to the market opportunity for fostamatinib as ...

| --- | --- | --- | |-------------------------|-------|-------| | | | | | | | | | | | | | | | | | Q4 and YE '20 Financial | | | | March 2021 Presentation | | | | | | | Forward-Looking Statement This presentation contains forward-looking statements relating to, among other things, the commercial success of TAVALISSE in the U.S. and TAVLESSE in Europe; Rigel's ability to achieve development, regulatory and commercial milestone payments; as well as tiered royalties; Rigel's expected operating results for the y ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2020 Earnings Conference Call March 2, 2021 4:30 PM ET Company Participants Dolly Vance – Executive Vice President-Corporate Affairs and General Counsel Raul Rodriguez – President and Chief Executive Officer Dave Santos – Chief Commercial Officer Wolfgang Dummer – Executive Vice President and Chief Medical Officer Esteban Masuda – Executive Vice President-Research Dean Schorno – Executive Vice President and Chief Financial Officer Conference Call Participants Yig ...